Who has been buying BL Pharmtech stock?

1 distinct insiders have filed 7 disclosed insider purchases in BL Pharmtech (065170), most recently on 2026-01-20. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does BL Pharmtech have?

BL Pharmtech has 7 buy-side and 0 sell-side disclosures on record, covering ₩550M ($382K) in total reported value, spanning 2024-03-28 to 2026-01-20.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

BL Pharmtech 065170

Company

비엘팜텍BL Pharmtech

Insiders

Buys

Total Value

₩550M ($382K)

Avg Return

+684.93%

Last Filing

2026-01-20

BL Pharmtech (065170) has 7 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩550M ($382K) in reported transaction value. The earliest filing StockDrifts holds for BL Pharmtech is dated 2024-03-28; the most recent is 2026-01-20. Across these filings the average return since disclosure is +684.93%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-01-20	BUY	Market Buy	박영철 Youngcheol Park	CEO	14.0K	₩579	+704.8%	₩8M ($6K)
2026-01-15	BUY	Market Buy	박영철 Youngcheol Park	CEO	15.0K	₩635	+633.9%	₩10M ($7K)
2026-01-14	BUY	Market Buy	박영철 Youngcheol Park	CEO	50.0K	₩489	+853.0%	₩24M ($17K)
2026-01-13	BUY	Market Buy	박영철 Youngcheol Park	CEO	20.7K	₩532	+775.9%	₩11M ($8K)
2026-01-12	BUY	Market Buy	박영철 Youngcheol Park	CEO	60.1K	₩512	+810.2%	₩31M ($21K)
2025-02-27	BUY	무상신주취득	송상근 Song Sang-geun	thanks	40.0K	₩1,878	+148.1%	₩75M ($52K)
2025-02-27	BUY	무상신주취득	신동진 Shin Dong-jin	Internal director	217.7K	₩1,878	+148.1%	₩409M ($284K)
2025-02-27	BUY	무상신주취득	박영철 Youngcheol Park	CEO	4.5M	₩1,878	+148.1%	₩8.5B ($5.9M)
2024-12-15	SELL	자본감소	박영철 Youngcheol Park	CEO	-20.3M	₩766	-508.4%	₩15.5B ($10.8M)
2024-12-15	SELL	자본감소	신동진 Shin Dong-jin	Internal director	-979.8K	₩766	-508.4%	₩751M ($521K)
2024-12-15	SELL	자본감소	송상근 Song Sang-geun	thanks	-180.2K	₩766	-508.4%	₩138M ($96K)
2024-12-13	BUY	Market Buy	박영철 Youngcheol Park	CEO	477.5K	₩766	+508.4%	₩366M ($254K)
2024-12-12	BUY	Market Buy	박영철 Youngcheol Park	CEO	131.2K	₩766	+508.4%	₩101M ($70K)
2024-03-28	BUY	신규선임	송상근 Song Sang-geun	thanks	200.2K	₩1,579	+195.1%	₩316M ($220K)
2024-03-28	BUY	신규선임	박영철 Youngcheol Park	CEO	21.9M	₩1,579	+195.1%	₩34.6B ($24.0M)
2024-03-28	BUY	신규선임	신동진 Shin Dong-jin	Internal director	1.1M	₩1,579	+195.1%	₩1.7B ($1.2M)
2024-03-28	SELL	장외매도	모아라이프플러스 Moa Life Plus	-	-21.7M	₩1,579	-195.1%	₩34.3B ($23.8M)

Frequently asked questions

Who has been buying BL Pharmtech stock?: 1 distinct insiders have filed 7 disclosed insider purchases in BL Pharmtech (065170), most recently on 2026-01-20. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does BL Pharmtech have?: BL Pharmtech has 7 buy-side and 0 sell-side disclosures on record, covering ₩550M ($382K) in total reported value, spanning 2024-03-28 to 2026-01-20.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.